A Phase 1 Single Dose Study of E6130 in Japanese Healthy Adult Male Subjects
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 22 Jun 2017
At a glance
- Drugs E 6130 (Primary)
- Indications Inflammatory bowel diseases
- Focus Adverse reactions
- Sponsors EA Pharma
- 02 Jun 2017 Status changed from recruiting to active, no longer recruiting.
- 20 Feb 2017 Planned End Date changed from 1 Mar 2018 to 1 Sep 2017.
- 27 Sep 2016 New trial record